NLY01 is a glucagon-like peptide-1 receptor (GLP-1R) inhibitor that can exert neuroprotective effects by directly regulating the activated microglia-mediated transformation of astrocytes to the A1 neurotoxic phenotype in PD (Yun et al., 2018). This evidence concerns the gene GLP1R and Parkinson disease.